Introduction {#Sec1_59}
============

*Helicobacter pylori* is the causative agent of gastritis, peptic ulcer disease (PUD), MALT lymphoma and a risk factor in the development of gastric cancer (Blaser and Berg [@CR3_59]). It has also been classified as a class I carcinogen by the International Agency for Research on Cancer (IARC) Monogr Eval Carcinog Risks Hum [@CR8_59](an arm of WHO) in 1994. The mode of transmission still unknown, although epidemiologic studies suggest close person to person contact, intrafamilial spread. There is still uncertainty whether transmission occurs primarily through faecal-oral or gastric-oral route (Covacci *et al*., [@CR4_59]). There are various tests for *H. pylori* diagnoses broadly categorized into two: invasive and non-invasive (Mégraud and Lehours[@CR13_59]). Invasive methods require endoscopy while the non-invasive methods do not. The invasive methods include culture (which is the gold standard), Rapid urease tests (RUT), histology, direct gram stain, PCR based methods and fluorescence *in situ* hybridization (FISH). The non-invasive methods include serology (which does not measure active infection), urea breath tests (UBT) (both ^13^C and ^14^C, gold standard, which is an expensive test and cannot be available in routine clinical laboratories), *Helicobacter pylori* stool antigen tests (HpSA) (Mégraud and Lehours [@CR13_59]).

*Helicobacter pylori* can be detected in stool specimens either by culture (difficult due to diverse microorganisms in the stool and fastidious nature of *H. pylori*), HpSA (discrepancies also occur from one geographical area to the other) and stool-PCR (with success rates of 25%--100%). Generally, the differences in detection rate of *H. pylori* in stool is due to *H. pylori* degradation in the gastrointestinal tract and/or presence of inhibitors such as complex polysaccharides and also its presence in low concentration in stools (Kabir [@CR9_59]).

Many PCR methods have been developed to detect the organism directly in different clinical specimens. Various authors have reported on the use of stool-PCR for diagnosis of *H. pylori* (Şen et al. [@CR16_59]; Hirai et al. [@CR7_59]; Aktepe et al. [@CR1_59]). The sensitivity with this method in recent times has varied from 21%--65.22% (Aktepe et al.[@CR1_59]; Şen et al. [@CR16_59]). However non-invasive methods that give accurate results are sought after. The study is therefore aimed at detecting *H. pylori* in stools of patients with dyspepsia using stool-PCR.

Materials and methods {#Sec2_59}
=====================

Study period: August 2009--April 2010.

Ethical approval was obtained from NIMR-IRB, while informed consent was obtained from patients before stool samples were taken.

Inclusion Criteria: patients not on antibiotics or PPI's/histamine- 2- receptor blockers at least a month before the study as well as presenting with dyspepsia symptoms.

Exclusion Criteria: those currently on antibiotics and or PPI's/histamine 2 receptor blockers.

Clinical samples {#Sec3_59}
----------------

Sampling method: Convenient sampling. Stool samples from 97 dyspeptic patients at the LUTH were used for this study. The stool samples were collected using sterile toothpicks into eppendorf tubes containing 700 μl absolute ethanol at room temperature. The samples was considered *H*. *pylori*- positive when *glmM* gene or both genes (*glmM* and *cagA*) were detected by PCR, and the results compared with those from UBT as the gold standard and confirmatory test.

UBT {#Sec4_59}
---

To screen for UBT, *H*. *pylori* testing was performed using a validated Heliprobe system (Noster AB Sweden). The heliprobe UBT is a ^14^C-based urea breath test for the detection of *H. pylori* infection. It comprises the Helicap TM capsule which contains the ^14^C-labelled urea which is swallowed and metabolized to carbon dioxide and ammonia by the urease enzyme produced by *H. pylori*. Labeled ^14^ C exhaled in the breath is captured by a breathcard and analysed by the automatic heliprobe analyser. Levels above 50 counts/min were considered positive of *H. pylori* infection.

Stool-PCR {#Sec5_59}
---------

### 16SrRNA gene (399 bp) {#Sec6_59}

Briefly, DNA from the stool samples were purified using the QIAamp® DNA Stool Mini kit (Hilden, Germany) containing an inhibitEX (removes all DNA damaging substances and PCR inhibitors in stool), and detected using a PCR assay targeting a 399 bp fragment of the 16S rRNA gene of *Helicobacter* spp. with two specific primers, *Heli*F (AAC GAT GAA GCT TCT AGC TTG CTA G) and *Heli*R (GTG CTT ATT CST NAG ATA CCG TCA T) (Germani et al. [@CR5_59]). PCR was performed using the Ready To-Go PCR beads kit by GE Healthcare (Buckinghamshire, UK). Amplification was carried out in an Eppendorf Mastercycler gradient (Hamburg, Germany) using the following cycling parameters: An initial denaturation at 94°C for 5 min and 35 cycles of 94°C for 30 s, 56°C for 1 min and 72°C for 1 min. This was followed by a final extension of 72°C for 10 min.

The PCR product was separated on a 2% Agarose gel and 50 bp ladder was used as DNA molecular weight standard.

### *cag*A gene (128 bp) {#Sec7_59}

PCR amplification using this primer was carried out using the primer set cagA-F : 5^′^-ATAATGCTAAATTAGACAACTTGAGCGA-3^′^ and 5^′^-AGAAACAAAAGCAATACGATCATTC-3^′^ Rugge et al. ([@CR15_59]). The 25 μl reaction mixture consisted of x1 PCR buffer, 1.5 mM Magnesium Chloride, 200 μM of each dNTP, 20pmol of each primer and 1U Taq DNA polymerase (Promega).

Amplification was carried out in an Eppendorf Mastercycler gradient using the following cycling parameters: an initial denaturation at 94°C for 5 min and 40 cycles of 94°C for 1 min, 54°C for 1 min and 72°C for 1 min. This was followed by a final extension of 72°C for 5 min. The PCR product was separated on a 2% Agarose gel and 50 bp ladder was used as DNA molecular weight standard.

### *glmM* gene (294 bp) {#Sec8_59}

The following primers were used: F : 5^′^-GGATAAGCTTTTAGGGGTGTTAGGGG-3^′^ (738--763) and R : 5^′^-GCTTACTTTCTAACACTAACGCGC-3^′^(1010--1033) Kansau et al. ([@CR10_59]). The 25 μl reaction mixture consisted of x1 PCR buffer, 1.5 mM Magnesium Chloride, 200 μM of each dNTP, 20pmol of each primer and 1U Taq DNA polymerase (Promega).

The following were the conditions for amplification: one cycle of denaturation at 94°C × 5 min; 35 cycles at 94°C × 1 min, annealing at 56°C × 1 min, and elongation at 72°C × 2 min, followed by a final elongation step by 1 cycle at 72°C × 7 min. 15°C and amplification was carried out in an Eppendorf Master cycler gradient (Hamburg). The PCR product was separated on a 2% Agarose gel and 50 bp ladder was used as DNA molecular weight standard.

Sensitivity of the primers was determined by testing other bacterial strains from related genus e.g. *Salmonella* Typhimurium and *E*. *coli*. The results of the *glm*M gene was compared with the gold standard (UBT) using the positive and negative predictive values and also the sensitivity and specificity.

The *glm*M and *cag*A genes are genes commonly used for the diagnosis of *H. pylori* directly from biopsy specimens as well as isolates and was therefore adapted for use for stool PCR in this study.

Results {#Sec9_59}
=======

None of the *Salmonella Typhimurium* or *E. coli* amplified with the set of specific primers for 16S rRNA and *glmM* genes.

Out of 97 stool samples analysed, *Helicobacter* spp. and *H. pylori* DNA were detected in 38 (39.2%) and 20 (20.6%) by 16S rRNA and *glm*M genes respectively. The detection of *cagA* positivity by PCR was observed in 8 out of 20 (40%) samples positive for *glm*M gene whereas 47 out of 97 (48.5%) samples were positive for *H. pylori* by UBT (Table [1](#Tab1){ref-type="table"}). Those simultaneously positive for stool-PCR (*glmM* gene) and UBT were 20 (42.6%) while 27 (57.5%) were positive for UBT and negative for stool-PCR using *glmM* gene. Table [2](#Tab2){ref-type="table"} shows the evidenced genes (*cag*A and *glm*M) and the subspecies. The sensitivity and specificity of the *glmM* gene compared with UBT as the gold standard is 42.6% and 100% respectively. The positive predictive value (PPV) was 100% while the negative predictive value (NPV) was 60%.Table 1**Results of stool PCR test using*glmM*gene with UBT as the gold standard**Results for stool-PCR, ***glm***M gene (n = 97)PositiveNegativeTotalSensitivitySpecificityPPVNPVUBT (n = 97)Positive2027**47**42.60%100%100.00%60.00%Negative050**50**Total**207797**Table 2**shows*cag*A +*glm*M genes with the subspecies,*Helicobacter*spp. and*H. pylori**Helicobacter*** spp. (16S rRNA)***H. pylori****cag*A+*glm*M88*glm*M1012*cag*A, *glm*M -20-Total3820

Figure [1](#Fig1){ref-type="fig"} and [2](#Fig2){ref-type="fig"} shows the PCR amplification of the samples using *glm*M and 16S rRNA genes respectively.Figure 1**Gel electrophoresis of PCR products amplified using the glmM gene for H. pylori. Lanes: M: molecular weight marker; -: negative control, +: positive control; 1 -- 7 samples.**Figure 2**Gel electrophoresis of PCR products amplified using the 16S rRNA gene of Helicobacter spp. Lanes**: M: molecular weight marker; 1: positive control, 2: negative control; 3 -- 12 samples.

Discussion {#Sec10_59}
==========

Non-invasive tests can play an important role in the diagnosis of *H. pylori* infections. However, all have their limitations in terms of cost, specificity, and sensitivity. The data presented here, are the results of a pilot study that preceded a project encompassing for UBT and PCR in monitoring a larger dyspeptic patient population. The 16S rRNA PCR amplified *Helicobacter* DNA (39%) in stool samples, being the most widely used method for detection of *H. pylori* in clinical specimens. However, the *glmM* gene PCR is the most sensitive and specific for the detection of *H. pylori* in gastric biopsy specimens Lu et al. ([@CR11_59]). The presence of *H. pylori* DNA was found in stool samples (21%). The results show that to some extent the *glmM* gene for detection of *H*. *pylori* DNA by PCR may be useful for the diagnosis of *H. pylori* from stool. In comparison with UBT as the gold standard, the sensitivity and specificity was 42.6% and 100%, respectively. The sensitivity is low. In a related study by Aktepe et al. ([@CR1_59]); using five methods of detection of *H. pylori*, the stool-PCR had the lowest sensitivity (21%). However, Makristathis et al. ([@CR12_59]) developed a semi-nested PCR assay, targeted to a species-specific protein antigen which is present in all strains of *H. pylori*, for detection and follow-up of *H. pylori* infected patients and the sensitivity was as high as 93.7% and the specificity was 100%. Another study by Mishra et al. ([@CR14_59]) corroborated the high sensitivity of stool-PCR in both pre-eradication and post-eradication to be 72.5% and 97.1% and the authors concluded that stool-PCR was better indicator than HpSA test in post-eradication assessment of infection. Another report by Gramley et al. ([@CR6_59]) reported sensitivity of stool-PCR to be 73%.

In this study, *cag*A gene was present in 40% of the samples positive for *H. pylori* by *glm*M gene and in a related study by Bindayna et al. ([@CR2_59]), *cag*A gene was found to be present in 22.7% this is lower than in our study. *cag*A positive *H. pylori* strains have been associated with severity of disease outcome and plays a critical role in the development of stomach cancer. From our previous studies with gastric biopsy specimens, *cag*A positive *H. pylori* was found in 68% of the biopsy specimens (Smith *et al*. [@CR17_59]); while from a related study by Bindayna et al. ([@CR2_59]) 59% of the biopsy samples were positive for *cag*A gene, when compared with 22.7% from stool samples. It goes to show the low prevalence of *cag*A gene in stool samples when compared to biopsy samples and this could be attributable to low numbers of *H. pylori* in stool samples as well as problems of faecal PCR inhibitors although the Qiagen kit was used to circumvent this in our study. In terms of high sensitivity and specificity found in studies with stool PCR these could be due to methods of DNA extraction as well as different targets used for detection of *H. pylori* by PCR. In addition, *glmM* and *cagA* genes have not been found yet in *Helicobacter* spp. other than *H. pylori*, suggesting that non-*H. pylori* helicobacters species may be commonly found in the stool of humans.

The PCR using *H. pylori* species specific primers in the long run could be also useful especially when infants, or very young children and patients with certain neurological disorders are being screened and UBT cannot be convenient for them. The method is also convenient for sample collection and samples can even be collected at home.

The method using the Qiagen stool mini kit is expensive but inexpensive methods that could help remove inhibitors in stool could be used to reduce cost e.g. filteration of stool and column chromatography.

From our study this method is not suitable for routine clinical setting in the developing countries but could be restricted to Reference labs where issues bordering on recurrent *H*. *pylori* infections and treatment failure are a problem especially where culture is difficult due to power outages in the developing countries. This study did not look at very young children due to the convenient sampling method which was biased.

The advantages and disadvantages of this method in our lab is as follows:

Advantages of stool-PCR It is non-invasiveIt can be used in children and most especially those with neurological disorders.It is useful for early screening in children to enable prompt detection of *H. pylori* related infection and aid in subsequent treatment.It would capture the generality of children, especially the under 10, as most hospitals don't have child endoscopes so it becomes difficult to screen children thoroughly due to lack of child endoscopes.

Disadvantages It is expensive for use in developing countries as long as the qiagen kit is employed.It might not be readily available in most diagnostic labs as with other PCR related methods and so has to be restricted to reference labs.

In conclusion, it could be most useful for diagnosis of *H*. *pylori* in children especially as endoscope for children is lacking.
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